Kalaris Therapeutics Ownership | Who Owns Kalaris Therapeutics?

Kalaris Therapeutics Ownership Summary

Kalaris Therapeutics is owned by 80.68% institutional investors, 9.90% insiders, and 9.42% retail investors. Samsara biocapital is the largest institutional shareholder, holding 56.54% of KLRS shares. Vanguard Morn Total Stk Mkt Idx Investor is the top mutual fund, with 1.07% of its assets in Kalaris Therapeutics shares.

KLRS Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Kalaris Therapeutics	80.68%	9.90%	9.42%
Sector	Healthcare Stocks	50.59%	12.40%	37.01%
Industry	Biotech Stocks	49.10%	12.14%	38.76%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Samsara biocapital	12.95M	56.54%	$74.71M
Rtw investments, lp	1.30M	5.68%	$7.50M
Alyeska investment group	572.69K	2.50%	$3.27M
Tang capital management	418.24K	2.24%	$2.42M
Siren	435.80K	1.90%	$2.51M
Ikarian capital	360.00K	1.57%	$2.08M
Vanguard group	292.79K	1.57%	$2.47M
Raymond james financial	118.89K	0.52%	$685.98K
Goldman sachs group	110.50K	0.48%	$637.60K
Woodline partners lp	100.00K	0.44%	$577.00K

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Samsara biocapital	12.95M	7.26%	$74.71M
Ikarian capital	360.00K	0.17%	$2.08M
Tang capital management	418.24K	0.09%	$2.42M
Rtw investments, lp	1.30M	0.07%	$7.50M
Siren	435.80K	0.07%	$2.51M
Velan capital investment management lp	18.00K	0.07%	$103.86K
Stonepine capital management	20.40K	0.05%	$117.71K
Wealthtrust asset management	12.42K	0.04%	$71.64K
Fortis capital advisors	40.00K	0.03%	$230.80K
Nano cap new millennium growth fund l p	4.00K	0.02%	$23.08K

Top Buyers

Holder	Shares	% Assets	Change
Alyeska investment group	572.69K	0.01%	169.14K
Vanguard group	292.79K	-	89.74K
Goldman sachs group	110.50K	0.00%	76.20K
Tang capital management	418.24K	0.09%	57.38K
Susquehanna group, llp	52.68K	-	39.83K

Top Sellers

Holder	Shares	% Assets	Change
Paradigm biocapital advisors lp	-	-	-700.00K
Octagon capital advisors lp	-	-	-360.00K
Gilead sciences	-	-	-317.79K
Propel bio management	-	-	-295.77K
Ecor1 capital	-	-	-201.72K

New Positions

Holder	Shares	% Assets	Change	Value
Vanguard fiduciary trust	36.72K	0.00%	36.72K	$211.86K
Stonepine capital management	20.40K	0.05%	20.40K	$117.71K
Velan capital investment management lp	18.00K	0.07%	18.00K	$103.86K
Independent advisor alliance	14.23K	0.00%	14.23K	$82.11K
Wealthtrust asset management	12.42K	0.04%	12.42K	$71.64K

Sold Out

Holder	Change
Eversource wealth advisors	-30.00
Farther finance advisors	-33.00
Federated hermes	-34.00
Royal bank of canada	-103.00
Fortitude family office	-114.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	57	11.76%	18,478,771	2.68%	80	0.87%	31	-8.82%	7	-
Dec 31, 2025	19	-38.71%	748,273	-94.34%	4	0.08%	11	-35.29%	4	-20.00%
Sep 30, 2025	11	-62.07%	388,919	-97.09%	2	0.04%	7	-41.67%	2	-71.43%
Jun 30, 2025	29	-6.45%	13,362,268	-3.69%	329	5.99%	12	-61.29%	7	-
Mar 31, 2025	31	-	13,874,350	-	74	-	31	-	-	-

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Morn Total Stk Mkt Idx Investor	255.34K	1.07%	-
Vanguard Total Stock Mkt Idx Inv	255.34K	1.07%	-
Vanguard MStar Total Stk Mkt Idx Invest	255.34K	1.07%	-
Vanguard Institutional Extnd Mkt Idx Tr	137.37K	0.58%	-
Simplify Propel Opportunities ETF	57.76K	0.25%	-
Fidelity Extended Market Index	59.38K	0.25%	24.81K
iShares Micro-Cap ETF	25.58K	0.11%	-342.00
Bridgeway Ultra-Small Company Market	22.50K	0.10%	-
EA Bridgeway Ultra-Small Company Mkt ETF	22.50K	0.09%	-
Fidelity Nasdaq Composite Index	16.28K	0.07%	-548.00

Recent Insider Transactions

Date	Name	Role	Activity	Value
May 20, 2026	AKKARAJU SRINIVAS		Buy	$1.18M
Mar 20, 2026	Hagen Brett R	Chief Accounting Officer	Sell	$12.87K
Dec 18, 2025	AKKARAJU SRINIVAS		Buy	$5.00M
Mar 26, 2025	Hagen Brett R	Chief Accounting Officer	Sell	$8.14K

Insider Transactions Trends

Date	Buy	Sell
2026 Q3	-	-
2026 Q2	1	-
2026 Q1	-	1
2025 Q4	1	-
2025 Q2	-	-

KLRS Ownership FAQ

Who Owns Kalaris Therapeutics?

Kalaris Therapeutics shareholders are primarily institutional investors at 80.68%, followed by 9.90% insiders and 9.42% retail investors. The average institutional ownership in Kalaris Therapeutics's industry, Biotech Stocks , is 49.10%, which Kalaris Therapeutics exceeds.

Who owns the most shares of Kalaris Therapeutics?

Kalaris Therapeutics’s largest shareholders are Samsara biocapital (12.95M shares, 56.54%), Rtw investments, lp (1.3M shares, 5.68%), and Alyeska investment group (572.69K shares, 2.50%). Together, they hold 64.71% of Kalaris Therapeutics’s total shares outstanding.

Does Blackrock own Kalaris Therapeutics?

BlackRock is not among the top 10 institutional shareholders of Kalaris Therapeutics.

Who is Kalaris Therapeutics’s biggest shareholder by percentage of total assets invested?

Samsara biocapital is Kalaris Therapeutics’s biggest shareholder by percentage of total assets invested, with 7.26% of its assets in 12.95M Kalaris Therapeutics shares, valued at 74.71M$.

Who is the top mutual fund holder of Kalaris Therapeutics shares?

Vanguard Morn Total Stk Mkt Idx Investor is the top mutual fund holder of Kalaris Therapeutics shares, with 1.07% of its total shares outstanding invested in 255.34K Kalaris Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools